Increased stathmin correlates with advanced stage and poor survival of non-small cell lung cancer

Durm G. and Hanna N. , Second-Line Chemotherapy and Beyond for Non-Small Cell Lung Cancer, Hematol Oncol Clin North Am 31 (2017), 71-81.

Heist R.S. , First-Line Systemic Therapy for Non-Small Cell Lung Cancer, Hematol Oncol Clin North Am 31 (2017), 59-70.

Chen W. , Zheng R. , Baade P.D. , Zhang S. , Zeng H. , Bray F. , Jemal A. , Yu X.Q. and He J. , Cancer statistics in China, 2015, CA Cancer J Clin 66 (2016), 115-132.

Biaoxue R. , Xiguang C. and Shuanying Y. , Annexin A1 in malignant tumors: current opinions and controversies, Int J Biol Markers 29 (2014), e8-20.

Villalobos P. and Wistuba II. , Lung Cancer Biomarkers, Hematol Oncol Clin North Am 31 (2017), 13-29.

Yurong L. , Biaoxue R. , Wei L. , Zongjuan M. , Hongyang S. , Ping F. , Wenlong G. , Shuanying Y. and Zongfang L. , Stathmin overexpression is associated with growth, invasion and metastasis of lung adenocarcinoma, Oncotarget DOI: 10.18632/oncotarget.11006 (2016).

Belletti B. and Baldassarre G. , Stathmin: A protein with many tasks. New biomarker and potential target in cancer, Expert Opin Ther Targets 15 (2011), 1249-1266.

Kim J.Y. , Harvard C. , You L. , Xu Z. , Kuchenbecker K. , Baehner R. and Jablons D. , Stathmin is overexpressed in malignant mesothelioma, Anticancer Res 27 (2007), 39-44.

Nakashima D. , Uzawa K. , Kasamatsu A. , Koike H. , Endo Y. , Saito K. , Hashitani S. , Numata T. , Urade M. and Tanzawa H. , Protein expression profiling identifies maspin and stathmin as potential biomarkers of adenoid cystic carcinoma of the salivary glands, Int J Cancer 118 (2006), 704-713.

Nie W. , Xu M.D. , Gan L. , Huang H. , Xiu Q. and Li B. , Overexpression of stathmin 1 is a poor prognostic biomarker in non-small cell lung cancer, Lab Invest 95 (2015), 56-64.

Biaoxue R. , Xiling J. , Shuanying Y. , Wei Z. , Xiguang C. , Jinsui W. and Min Z. , Upregulation of Hsp90-beta and annexin A1 correlates with poor survival and lymphatic metastasis in lung cancer patients, J Exp Clin Cancer Res 31 (2012), 70.

Fiore E. , Campani D. , Muller I. , Belardi V. , Giustarini E. , Rossi G. , Pinchera A. and Giani C. , IGF-II mRNA expression in breast cancer: predictive value and relationship to other prognostic factors, Int J Biol Markers 25 (2010), 150-156.

Kouzu Y. , Uzawa K. , Koike H. , Saito K. , Nakashima D. , Higo M. , Endo Y. , Kasamatsu A. , Shiiba M. , Bukawa H. , Yokoe H. and Tanzawa H. , Overexpression of stathmin in oral squamous-cell carcinoma: Correlation with tumour progression and poor prognosis, Br J Cancer 94 (2006), 717-723.

Reyes H. , Bosquet J. , Stephan J. , McDonald M. and Leslie K. , Stathmin over-expression correlates with poor prognosis in patients with endometrial cancer, Gynecol Oncol 137 (2015), 66.

Jeon T.Y. , Han M.E. , Lee Y.W. , Lee Y.S. , Kim G.H. , Song G.A. , Hur G.Y. , Kim J.Y. , Kim H.J. , Yoon S. , Baek S.Y. , Kim B.S. , Kim J.B. and Oh S.O. , Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells, Br J Cancer 102 (2010), 710-718.

Hsieh S.Y. , Huang S.F. , Yu M.C. , Yeh T.S. , Chen T.C. , Lin Y.J. , Chang C.J. , Sung C.M. , Lee Y.L. and Hsu C.Y. , Stathmin1 overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma, Mol Carcinog 49 (2010), 476-487.

Rong B. , Jiang X. , Yang S. , Zhang W. , Cai X. , Wang J. and Zhang M. , Upregulation of Hsp90-beta and annexin A1 correlates with poor survival and lymphatic metastasis in lung cancer patients, Journal of Experimental & Clinical Cancer Research 31 (2012).

Yuan R.H. , Jeng Y.M. , Chen H.L. , Lai P.L. , Pan H.W. , Hsieh F.J. , Lin C.Y. , Lee P.H. and Hsu H.C. , Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma, J Pathol 209 (2006), 549-558.

Sonego M. , Schiappacassi M. , Lovisa S. , Dall'Acqua A. , Bagnoli M. , Lovat F. , Libra M. , D'Andrea S. , Canzonieri V. and Militello L. , Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer, EMBO Molecular Medicine 5 (2013), 707-722.

Biaoxue R. , Xiguang C. , Hua L. and Shuanying Y. , Stathmin-dependent molecular targeting therapy for malignant tumor: The latest 5 years' discoveries and developments, J Transl Med 14 (2016), 279.

Wu Y. , Tang M. , Weng X. , Yang L. , Xu W. , Yi W. , Gao J. , Bode A.M. , Dong Z. and Cao Y. , A combination of paclitaxel and siRNA-mediated silencing of Stathmin inhibits growth and promotes apoptosis of nasopharyngeal carcinoma cells, Cell Oncol (Dordr) 37 (2014), 53-67.

Yuan S.F. , Chen W.J. , Zhu L.J. , Zheng W.E. , Chen H. and Xiong J.P. , Effects of monoclonal antibodies against human stathmin combined with paclitaxel on proliferation of the QG-56 human lung carcinoma cell line, Asian Pac J Cancer Prev 13 (2012), 2967-2971.

Long M. , Yin G. , Liu L. , Lin F. , Wang X. , Ren J. , Wei J. , Dong K. and Zhang H. , Adenovirus-mediated Aurora A shRNA driven by stathmin promoter suppressed tumor growth and enhanced paclitaxel chemotherapy sensitivity in human breast carcinoma cells, Cancer Gene Ther 19 (2012), 271-281.

Nie W. , Xu M.-D. , Gan L. , Huang H. , Xiu Q. and Li B. , Overexpression of stathmin 1 is a poor prognostic biomarker in non-small cell lung cancer, Laboratory Investigation 95 (2015), 56-64.